Interval Versus Continuous Exercise During Pregnancy

Sponsor
University of Alberta (Other)
Overall Status
Recruiting
CT.gov ID
NCT05369247
Collaborator
(none)
32
1
2
21.9
1.5

Study Details

Study Description

Brief Summary

The objective of this randomized cross-over design was to investigate the fetal well-being and maternal glycemic response to an acute bout of aerobic high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT) with pregnant individuals.

Condition or Disease Intervention/Treatment Phase
  • Other: High intensity Interval Training
  • Other: Moderate Intensity Continuous Training
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Effects of Acute High-intensity Intervals Versus Moderate-intensity Continuous Cycling on Maternal and Fetal Health
Actual Study Start Date :
Dec 1, 2020
Anticipated Primary Completion Date :
Sep 30, 2022
Anticipated Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1st Exercise session

Participants completed either the HIIT or MICT session.

Other: High intensity Interval Training
HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., > 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).

Other: Moderate Intensity Continuous Training
The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).

Experimental: 2nd Exercise session

Participants completed the subsequent exercise protocol (i.e. HIIT or MICT)

Other: High intensity Interval Training
HIIT protocol consisted of 10 one-minute intervals of high-intensity work (i.e., > 90% HRmax) interspersed with nine one-minute intervals of self-paced active recovery (19-minutes total).

Other: Moderate Intensity Continuous Training
The MICT protocol consisted of 30-minutes of moderate intensity cycling (i.e., 64 - 76% HRmax).

Outcome Measures

Primary Outcome Measures

  1. Flash Glucose Monitor; interstitial Glucose [7-days]

    Measured by a Flash Glucose monitor inserted onto the back of the left tricep

  2. Fetal Heart Rate [3-minutes]

    Measured via ultrasound pre and post exercise

  3. Fetal Umbilical Blood Flow [3-minutes]

    Measured Via ultrasound pre and post exercise

Secondary Outcome Measures

  1. Maternal Heart Rate [40-minutes]

    Measured via heart rate monitor; Measured prior to, during, and after exercise.

  2. Accelerometer [7-days]

    The investigators will objectively measure physical activity using an accelerometer for one week. Average number of minutes per day spent in various activity levels will be determined.

  3. Food Log [7-days]

    The investigators will objectively measure nutrients in diet using a seven day food record. This is completed through Food Prodigy/ Food Processor software.

  4. Perceived rating of perceived exertion [40-minutes]

    Borg Scale; Ratings from 6 - 20; Rating of six is minimal perceived exertion and rating of 20 is maximal perceived exertion.

  5. Cardiovascular fitness [20-minutes]

    Graded exercise test to volitional fatigue.

  6. Cerebral Blood Flow of Posterior cerebral artery [40-min]

    Measured using a trans cranial doppler ultrasound. Measured prior to, during, and after exercise.

  7. Sleep Quality [7-days]

    The investigators will objectively measure sleep quality using an accelerometer for one week. Average number of hours of sleep per night, time spent awake after sleep onset, and number of awakenings will be determined

  8. Rating of Perceived Enjoyment (1-10 Scale) [40-minutes]

    Rating of 1 is the lowest level of perceived enjoyment, rating of 10 is maximal perceived enjoyment

  9. Blood pressure [40-min]

    Measured with a finometer; Measured prior to, during, and after exercise.

  10. Cardiac Output [40-min]

    Measured with a finometer; Measured prior to, during, and after exercise.

  11. Cerebral blood flow of middle cerebral artery [40-minutes]

    Measured using a trans cranial doppler ultrasound. Measured prior to, during, and after exercise.

  12. fasted blood sample- sex hormones [5-minutes]

    Fasted blood samples (~30ml) will be analyzed for sex hormones (estrogen, progesterone, testosterone).

  13. Physical Activity Questionnaire [5-minutes]

    The participants will report physical activity using the pregnancy physical activity questionnaire (gives metabolic equivalent hours per week (MET-hr/week).

  14. Depression rating [5-minutes]

    Participants will answer a 10-question questionnaire regarding their mood. A score of 10 or higher is indicative of depressive symptoms. The investigators will report the over number of women in each group who have a score of 10+ at the start and end of the intervention.

  15. Respiratory measures - respiratory frequency [40-minutes]

    Breathing frequency (breaths per minute). Measured using spirometry.

  16. Respiratory measures - tidal volume [40-minutes]

    Tidal Volume (Liters per breath). Measured using spirometry.

  17. Respiratory measures - oxygen [40-minutes]

    Oxygen metabolism (% oxygen used per breath). Measured using a gas analyzer.

  18. Respiratory measures - carbon dioxide [40-minutes]

    Carbon Dioxide production (% carbon dioxide per breath). Measured using a gas analyzer.

  19. Respiratory measures - lung volume [40-minutes]

    Total Lung Capacity (Liters). Measured using spirometry.

  20. Fetal Outcome - birth weight [within one month postpartum]

    Participants will provide the investigators with birth weight for the infant (grams)

  21. fetal outcomes- length [within one month postpartum]

    Participants will provide the investigators with birth length for the infant (cm)

  22. fetal outcomes- gestational age [within one month postpartum]

    Participants will provide the investigators with gestational age at delivery (weeks)

  23. maternal outcomes- mode of delivery [within one month postpartum]

    Participants will provide the investigators with mode of delivery (vaginal or cesarean).

  24. maternal outcomes- delivery complications [within one month postpartum]

    Participants will provide the investigators with information regarding any delivery complications.

  25. maternal outcomes- pregnancy complications [any time during study]

    Participants will provide the investigators with information regarding any pregnancy complications (gestational diabetes, pregnancy induced hypertension, preeclampsia).

  26. fetal outcomes- NICU [within one month postpartum]

    Participants will provide the investigators with information regarding length (days) of admission to Neonatal Intensive Care Unit (NICU) if applicable

  27. maternal outcomes- gestational weight gain [within one month postpartum]

    Participants will provide the investigators with the last maternal weight immediately before delivery. This will be used to calculate gestational weight gain (kg; last maternal weight - self reported pre-pregnancy weight).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Carrying a singleton pregnancy (i.e. greater than or equal to 20 weeks of gestation).

  • Has access to a stationary bike

  • Located within Canada and/or within Edmonton Alberta

Exclusion Criteria:
  • History of smoking within the last year

  • Taking medications that may interfere with cardiovascular function.

  • High-order pregnancies, e.g. twins or above.

  • Females with absolute contraindications (as outlined by the Canadian Guidelines for Physical Activity throughout Pregnancy and the PARMed-X questionnaire)

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Alberta Edmonton Alberta Canada T6G 2R3

Sponsors and Collaborators

  • University of Alberta

Investigators

  • Principal Investigator: Margie H Davenport, PhD, University of Alberta

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Alberta
ClinicalTrials.gov Identifier:
NCT05369247
Other Study ID Numbers:
  • Pro00103630
First Posted:
May 11, 2022
Last Update Posted:
Jul 8, 2022
Last Verified:
Apr 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 8, 2022